A Phase I Clinical Study of Dendritic Cell Vaccine against Measles for Patients Following Hematopoietic Cell Transplantatio
Phase 1
- Conditions
- Post-HCT patients
- Registration Number
- JPRN-UMIN000006471
- Lead Sponsor
- Department of Pediatric and Developmental Science, Institute of Molecular and Experimental Medicine, Mie University Graduate School of Medicine
- Brief Summary
DC-based MV vaccine could be safely inoculated and would be effective in post-HCT patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
1. Have a recurrent or relapse of their diseases 2. Are pregnant or lactating. 3. Have psychiatric disorders that would interfere with consent, study participation, or follow-up. 4. Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or pancreas.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events
- Secondary Outcome Measures
Name Time Method serum-anti measles antibody titer